Syntex' low dose Tri-Norinyl
Executive Summary
Triphasic oral contraceptive product has been approved by FDA, firm said April 13. Maintaining that the product is "the lowest dose (overall hormonal content) multiphasic regimen" in the U.S., Syntex said that by varying the hormone content through the reproductive cycle unwanted side-effects such as breakthrough bleeding and spotting are reduced. Tri-Norinyl is available in either 21 or 28 day regimens. Price to whslrs. will be the same as for Brevicon and Norinyl, the firm's other low dose oral contraceptive products.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.